Results 161 to 170 of about 152,115 (284)

Preventive Effect of Mineralocorticoid Receptor Antagonists Against Proteinuria Induced by Atezolizumab Plus Bevacizumab Therapy in Hepatocellular Carcinoma: A Multicenter Retrospective Study

Hepatology Research, EarlyView.
Mineralocorticoid receptor antagonists are known to reduce proteinuria in chronic kidney disease, but their effectiveness in preventing bevacizumab‐related proteinuria has not been well established. In the present multi‐institutional retrospective study, we found that these agents significantly delay the onset of moderate or higher grade proteinuria ...
Tomoki Hori, Kazuhiro Yamamoto, Hiroshi Aoi, Yusuke Koizumi, Makoto Kuromatsu, Aiko Fukui, Hiroyo Okamoto, Atsushi Hirata, Kentaro Shinmori, Yuki Imanaka, Miyu Namba, Keisuke Nakanishi, Syunsuke Kitamura, Hideo Tsushima, Ikuko Yano, Kei Moriya, Masaru Matsui, Shigeki Ikushima   +17 more
wiley   +1 more source

Bevacizumab-Based Therapy Is Associated with Prolonged Progression-Free Survival in Patients with Peritoneal Mucinous Metastatic Colorectal Cancer. [PDF]

J Clin Med
Can S, Çakıcı V, Kahveci GB, Eroğlu Ş, Tok B, Uygun G, Özer E, Çırak Y, Gökmen İ.   +8 more
europepmc   +1 more source

Defining the tumor microenvironment of non‐small cell lung cancer

Immunology &Cell Biology, EarlyView.
The tumor microenvironment (TME) in non‐small cell lung cancer is highly heterogeneous, both at a patient level and tumor microenvironment resolution. Defining the tumor microenvironment from patient‐responders and non‐responders will aid in the development of targeted therapeutics specific for each individual patient.
Kidane Siele Embaye, Tony Blick, Vahid Yaghoubi Naei, Ken O'Byrne, Brett G. M. Hughes, Arutha Kulasinghe   +5 more
wiley   +1 more source

Complete and Rapid NMR Characterization of Therapeutic Monoclonal Antibodies via Differential Labeling of Fab Fragments in <i>Escherichia coli</i>. [PDF]

Anal Chem
Gagné D, Aubin Y.
europepmc   +1 more source

Glioblastoma mimicking anti‐NMDA receptor encephalitis: a case series

Internal Medicine Journal, EarlyView.
Abstract Anti‐N‐methyl‐D‐aspartate receptor (anti‐NMDAR) GluN1‐IgG antibodies are the hallmark of anti‐NMDAR encephalitis, a common type of autoimmune encephalitis. We describe two men with seizures and asymmetric, mass‐like temporal lesions initially treated as anti‐NMDAR encephalitis: Case 1 had serum and cerebrospinal fluid (CSF) NMDAR‐IgG ...
Sophie Chatterton, Fangzhi (Frank) Jia, Antonia J. Clarke, Laveniya Satgunaseelan, Hwei Choo Soh, Karl Ng, Kaitlyn Parratt, John Parratt   +7 more
wiley   +1 more source

Clinical outcomes of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil or regorafenib in metastatic colorectal cancer: a multicenter cohort study. [PDF]

ESMO Open
Moik F, Huemer F, Doleschal B, Taghizadeh H, Reimann P, Kostmann SM, Wagner L, Abdel Hamid M, Zimmer KC, Suppé SA, Bachleitner C, Schaberl-Moser R, Amann A, Wolf D, Greil R, Jost PJ, Winder T, Rumpold H, Weiss L, Gerger A, Seeber A, Riedl JM.   +21 more
europepmc   +1 more source

National survey of real‐world treatment patterns for early‐ and intermediate‐stage hepatocellular carcinoma reveals wide variation across Australian states

Internal Medicine Journal, EarlyView.
Abstract Background Hepatocellular carcinoma (HCC) is a heterogeneous and multi‐disease state that is complex to manage and requires a multidisciplinary approach to optimise patient care. Best practice recommendations were proposed in the Australian HCC consensus statement published in 2020.
Stuart K. Roberts, Ammar Majeed, Kiran Rasaratnam, John K. Olynyk, Nicholas Shackel, Marnie Wood, Alan Wigg, Simone I. Strasser   +7 more
wiley   +1 more source

Effectiveness of FTD/TPI plus bevacizumab and impact of prior bevacizumab exposure in patients with mCRC: the Italian FLOWER study. [PDF]

ESMO Gastrointest Oncol
Trovato G, Carullo M, Nicastro A, Spoto C, Perissinotto E, Giordano G, Di Giacomo E, Calegari MA, Pasquinucci V, Troiani T, Tamberi S, Schirripa M, Scartozzi M, Morano F, Arrivi G, Morelli C, Basso M, Landi M, Martinelli E, Zoratto F, Bergamo F, Landriscina M, Lucchetti J, Cremolini C, Tortora G, Salvatore L.   +25 more
europepmc   +1 more source

Systemic Therapy for Advanced Hepatocellular Carcinoma in 2026: Current Standard‐of‐Care and Emerging Therapeutic Strategies

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, accounting for up to 80% of all cases. Most patients present at an advanced stage and are unsuitable for curative treatments. In the past 5 years, immunotherapy combination has superseded tyrosine kinase inhibitors (TKI) as the standard first‐line therapy for ...
Landon L. Chan, Kallista O. K. Chan, Stephen L. Chan   +2 more
wiley   +1 more source

Enhanced Tumor-to-Background Contrast with [⁵²Mn]Mn-BPPA-Bevacizumab VEGF-Targeted Immuno-PET in Cervical Cancer. [PDF]

Pharmaceuticals (Basel)
Csikos C, Ngô MT, Vágner A, Nagy G, Ország G, Nagy T, Váradi B, Sajtos GZ, Kapus I, Szoboszlai Z, Szikra D, Tircsó G, Krasznai ZT, Molnár S, Garai I, Trencsényi G.   +15 more
europepmc   +1 more source